Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19300113 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | August 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19025939 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | January 2025 | November 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18909918 | MODIFIED DOUBLE-STRANDED RNA AGENTS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18885005 | Compositions and Methods Using CPG Oligonucleotides | September 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18814067 | MODIFIED DOUBLE-STRANDED RNA AGENTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18744370 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18590737 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | February 2024 | November 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18428353 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | January 2024 | April 2025 | Allow | 15 | 0 | 1 | No | No |
| 18426444 | RAAV-BASED COMPOSITIONS AND METHODS | January 2024 | January 2026 | Allow | 24 | 1 | 1 | No | No |
| 18416945 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (SINA) | January 2024 | September 2025 | Allow | 20 | 2 | 0 | No | No |
| 18410720 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | January 2024 | August 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18390233 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | December 2023 | June 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18534974 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS | December 2023 | June 2024 | Allow | 6 | 1 | 0 | No | No |
| 18523558 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18515531 | MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes | November 2023 | May 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18511908 | INHIBITION OF EXPANSION AND FUNCTION OF PATHOGENIC AGE-ASSOCIATED B CELLS AND USE FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASE | November 2023 | August 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18510877 | TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6 | November 2023 | December 2025 | Allow | 25 | 3 | 1 | No | No |
| 18504548 | GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR) | November 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18491658 | Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18487338 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18463079 | PANCREATIC CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | September 2023 | August 2024 | Allow | 12 | 0 | 0 | No | No |
| 18449230 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | August 2023 | July 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18446743 | Methods for Treatment of Alport Syndrome | August 2023 | March 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18365787 | Novel Structurally Designed shRNAs | August 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18361772 | PLATELETS AS DELIVERY AGENTS | July 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18346099 | ANTISENSE OLIGOMERS TARGETING PCSK9 | June 2023 | May 2025 | Allow | 23 | 1 | 1 | No | No |
| 18340192 | Conjugated Antisense Compounds for Use in Therapy | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18204383 | STAUFEN1 AGENTS AND ASSOCIATED METHODS | May 2023 | April 2025 | Allow | 23 | 2 | 1 | No | No |
| 18319977 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | May 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18320132 | SCARLESS GENOME EDITING THROUGH TWO-STEP HOMOLOGY DIRECTED REPAIR | May 2023 | July 2025 | Allow | 25 | 1 | 0 | No | No |
| 18037194 | ANTISENSE NUCLEIC ACID AND USE THEREOF | May 2023 | February 2026 | Allow | 33 | 1 | 0 | Yes | No |
| 18316409 | NUCLEASE-MEDIATED REPEAT EXPANSION | May 2023 | July 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18316693 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | May 2023 | November 2024 | Abandon | 18 | 2 | 1 | No | No |
| 18144275 | COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | May 2023 | October 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18305195 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | April 2023 | July 2025 | Allow | 27 | 1 | 0 | No | No |
| 18302841 | COMPOSITIONS AND METHODS FOR TREATMENT OF SEPSIS-RELATED DISORDERS | April 2023 | December 2024 | Allow | 20 | 1 | 1 | No | No |
| 18299531 | Stabilized saRNA Compositions and Methods of Use | April 2023 | April 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18194163 | VESICLES COMPRISING A PTEN INHIBITOR AND USES OF SAME | March 2023 | January 2026 | Abandon | 34 | 3 | 0 | No | No |
| 18167984 | METHODS FOR THERAPEUTIC ADMINISTRATION OF MESSENGER RIBONUCLEIC ACID DRUGS | February 2023 | October 2024 | Allow | 20 | 1 | 0 | No | No |
| 18168004 | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION | February 2023 | March 2025 | Allow | 25 | 2 | 0 | No | No |
| 18166204 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | February 2023 | October 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18018478 | Inhibition of lncExACT1 to Treat Heart Disease | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18159233 | 5-HALOURACIL-MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER | January 2023 | January 2025 | Allow | 24 | 2 | 0 | No | No |
| 18006455 | GENE EDITING TO IMPROVE JOINT FUNCTION | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18155552 | RAPID REMOVAL OF A SELF-REPLICATING FUNGAL PLASMID FOR EFFICIENT MARKER CYCLING | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18153428 | Oligonucleotides Comprising Modified Nucleosides | January 2023 | August 2024 | Allow | 20 | 1 | 1 | No | No |
| 18015054 | IMPROVED RNA EDITING METHOD | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18147156 | ARTIFICIAL GENOME MANIPULATION FOR GENE EXPRESSION REGULATION | December 2022 | August 2024 | Allow | 19 | 1 | 0 | No | No |
| 18145238 | Modified Double-Stranded RNA Agents | December 2022 | August 2024 | Allow | 19 | 1 | 1 | No | No |
| 18063511 | GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND ENGINEERED NANOPARTICLES TO PROVIDE TARGETED GENETIC THERAPIES | December 2022 | June 2025 | Allow | 30 | 1 | 1 | No | No |
| 18072202 | COMPOSITIONS AND METHODS FOR TREATING HYPERTRIGLYCERIDEMIA | November 2022 | March 2025 | Abandon | 27 | 1 | 0 | No | No |
| 18058212 | Nucleoporins as Drug Targets for Anti-Proliferative Therapeutics | November 2022 | October 2024 | Allow | 23 | 1 | 1 | No | No |
| 17990402 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED MINICELLS AND METHODS OF USING THE SAME | November 2022 | May 2025 | Allow | 30 | 2 | 1 | No | No |
| 17981146 | EXPRESSION CONTROL USING A REGULATABLE INTRON | November 2022 | December 2025 | Allow | 37 | 2 | 1 | No | No |
| 17976164 | DAMAGE-TARGETED TREATMENTS OF DISEASE | October 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 18045906 | INHIBITORS OF MICRO-RNA 22 | October 2022 | December 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 18046020 | CLICK-MODIFIED MRNA | October 2022 | November 2024 | Allow | 25 | 1 | 1 | No | No |
| 17963901 | GENE THERAPY FOR HAPLOINSUFFICIENCY | October 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 17912951 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | September 2022 | February 2026 | Allow | 41 | 1 | 1 | No | No |
| 17933500 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | September 2022 | October 2024 | Allow | 25 | 1 | 1 | No | No |
| 17931493 | DOMINANT ACTIVE YAP, A HIPPO EFFECTOR, INDUCES CHROMATIN ACCESSIBILITY AND CARDIOMYOCYTE RENEWAL | September 2022 | July 2024 | Allow | 22 | 1 | 0 | No | No |
| 17942698 | RNAS FOR COMPLEMENT INHIBITION | September 2022 | July 2024 | Allow | 22 | 1 | 1 | No | No |
| 17905942 | NOVEL USE OF ASPIRIN COMPOUND IN INCREASING NUCLEIC ACID EXPRESSION | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17941436 | MODIFIED DOUBLE-STRANDED RNA AGENTS | September 2022 | February 2025 | Allow | 29 | 1 | 1 | No | No |
| 17910293 | DECOY TRANSCRIPTS FOR TREATMENT OF ssRNA VIRAL INFECTION | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17910166 | CRISPR-AID USING CATALYTICALLY INACTIVE RNA-GUIDED ENDONUCLEASE | September 2022 | March 2026 | Allow | 42 | 1 | 0 | No | No |
| 17930345 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | September 2022 | June 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17929867 | Compositions and Methods for Suppressing MSUT2 | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17930062 | RNA FOR TREATMENT OR PROPHYLAXIS OF A LIVER DISEASE | September 2022 | October 2024 | Abandon | 26 | 0 | 2 | No | No |
| 17909148 | COMPOSITIONS AND METHODS FOR MODULATING RPGR EXPRESSION | September 2022 | December 2025 | Allow | 39 | 1 | 1 | No | No |
| 17900919 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17900960 | Modified Guide RNAs | September 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17908225 | ANTAGONIST OF PCSK9 | August 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17822668 | OLIGONUCLEOTIDES FOR MODULATING CD73 EXON 7 SPLICING | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17904597 | PREPARATION METHOD FOR DIABETES EARLY WARNING AND/OR DIAGNOSTIC REAGENT KIT BASED ON HSA-MIR-320A, MEDICAMENT FOR PREVENTING DIABETES, SCREENING METHOD FOR MEDICAMENT, AND PREPARATION METHOD THEREFOR | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17798468 | PHI29 MUTANTS AND USE THEREOF | August 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17884034 | SMALL INTERFERING DEOXYRIBONUCLEIC ACID (SIDNA) AGAINST METALLO-BETA LACTAMASE GENE | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17816995 | NUCLEIC ACID CONCATEMERS AND METHODS FOR STABILIZING AND/OR COMPACTING THE SAME | August 2022 | October 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17795560 | ANTISENSE OLIGONUCLEOTIDE TARGETING LINC00518 FOR TREATING MELANOMA | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17624125 | COMPOSITIONS AND METHODS FOR TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA | July 2022 | January 2026 | Allow | 49 | 2 | 0 | No | No |
| 17873239 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | July 2022 | December 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17814407 | RAPID AND SPECIFIC EX-VIVO DIAGNOSIS OF CENTRAL NERVOUS SYSTEM LYMPHOMA | July 2022 | January 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17812607 | COMPOUNDS AND COMPOSITIONS INCLUDING PHOSPHOROTHIOATED OLIGODEOXYNUCLEOTIDE, AND METHODS OF USE THEREOF | July 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17787687 | NOVEL TLR9 AGONISTS | June 2022 | March 2026 | Allow | 45 | 2 | 1 | No | No |
| 17787702 | METHOD FOR ALLEVIATING CANCER-INDUCED PAIN THROUGH CONTROL OF PAIN SIGNALS IN CENTRAL NERVOUS SYSTEM | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17785818 | Methods for Culturing Cancer Cells and for Inhibiting Invasion of Cancer | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17746360 | Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128 | May 2022 | March 2025 | Abandon | 34 | 3 | 1 | No | No |
| 17777135 | METHOD FOR PREDICTING SENSITIVITY OF CANCER CELL TO HELICASE INHIBITOR | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17662392 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | May 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17773456 | CD20 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE FOR IMMUNOTHERAPY | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17721704 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | April 2022 | October 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17768675 | METHODS AND COMPOSITIONS FOR TREATING UVEAL MELANOMA | April 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17768283 | PHARMACEUTICAL COMPOSITION CONTAINING DOUBLE-STRANDED RIBONUCLEIC ACID INHIBITING EXPRESSION OF COMPLEMENT C5 | April 2022 | July 2025 | Allow | 39 | 1 | 0 | No | No |
| 17718713 | METHODS, SYSTEMS AND COMPOSITIONS FOR TRAUMATIC BRAIN INJURY AND ASSOCIATED NEURODEGENERATIVE DISEASE IMMUNE RESPONSE DIAGNOSTICS | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17767190 | MODIFIED OLIGONUCLEOTIDES | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17764497 | DNA Binding Proteins for Displacing Endogenous Transcription Factors Bound to Gene Regulatory Regions | March 2022 | March 2026 | Allow | 47 | 1 | 1 | No | No |
| 17694224 | METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST BCLXL AND MCL1 USING A POLYPEPTIDE NANOPARTICLE | March 2022 | June 2025 | Abandon | 39 | 2 | 1 | No | Yes |
| 17688276 | INHIBITION OF DNA POLYMERASES BY URACIL-DNA GLYCOSYLASE-CLEAVABLE OLIGONUCLEOTIDE LIGANDS | March 2022 | August 2024 | Allow | 30 | 1 | 0 | No | No |
| 17417321 | SMALL RNA MEDICAMENT FOR PREVENTION AND TREATMENT OF INFLAMMATION-RELATED DISEASES AND COMBINATION THEREOF | February 2022 | January 2026 | Allow | 55 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUDSON, AMY ROSE.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HUDSON, AMY ROSE works in Art Unit 1636 and has examined 242 patent applications in our dataset. With an allowance rate of 95.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner HUDSON, AMY ROSE's allowance rate of 95.0% places them in the 84% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUDSON, AMY ROSE receive 1.74 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HUDSON, AMY ROSE is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +3.0% benefit to allowance rate for applications examined by HUDSON, AMY ROSE. This interview benefit is in the 25% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 35.3% of applications are subsequently allowed. This success rate is in the 79% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 52.3% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 90.0% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 61.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.3% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 24.8% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.